



PRESS RELEASE

## **ORCA Therapeutics strengthens Scientific Advisory Board**

**Amsterdam, The Netherlands – September 3<sup>th</sup>, 2013** – ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of Dr. Ronald Rodriguez. Dr. Rodriguez is currently Professor and Chairman of the Department of Urology at the University of Texas Health Science Center at San Antonio. He is an outstanding clinician and investigator focusing on prostate, bladder, and kidney cancer.

"We are very pleased to welcome Prof. Ron Rodriguez as member of ORCA's SAB" said Janneke Meulenberg, Chief Executive Officer of ORCA Therapeutics. "Dr. Rodriguez is an international renown expert in the field of urology, urological oncology and oncolytic virotherapy. His experience will be of great value as we are progressing towards clinical testing of our lead product ORCA-010 in prostate cancer patients".

Prof Ron Rodriguez will join existing members of ORCA's SAB: Prof. Frank McCormick, Director of the Helen Diller Family Comprehensive Cancer Center & Cancer Research Institute of the University of California; Prof. Winald Gerritsen, medical oncologist at the Radboud University Nijmegen Medical Centre; and Dr. Ramon Alemany, laboratory director in the Catalan Institute of Oncology. The SAB is guiding the company in the development of cancer therapies based on the unique functions of its proprietary oncolytic adenoviruses.

### **About ORCA Therapeutics**

ORCA Therapeutics BV is a biopharmaceutical company developing a pipeline of innovative anticancer therapies based on the highly promising approach of Oncolytic Replication Competent Agents (ORCA). ORCA Therapeutics' technology and IP portfolio originates from the research performed at the Department of Medical Oncology at the VU University Medical Center (VUmc) in Amsterdam, the Netherlands. The company has a platform of technologies that are predominantly based on highly engineered oncolytic adenoviruses. ORCA Therapeutics is currently preparing its lead product ORCA-010 for testing in clinical trials.

### **For more information, please contact:**

ORCA Therapeutics BV  
Janneke Meulenberg, CEO  
+31-204441826  
meulenberg@orca-therapeutics.com  
www.orca-therapeutics.com